Danol for Premenstrual Syndrome: A Preliminary Report of a Placebo-Controlled Double-Blind Study

In: Journal of International Medical Research · 1985 · vol. 13(2) , pp. 129–130 · doi:10.1177/030006058501300210 · PMID:3888728 · W2289750197
article OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-09

This double-blind, placebo-controlled study investigated the efficacy of danazol, a synthetic steroid, for treating premenstrual syndrome by suppressing hormonal fluctuations.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Introduction Danol (danazoI) is a synthetic steroid which has been found to be effective in the treatment of a variety of gynaecological and endocrinological disorders including endometriosis (Young & Blackmore 1977), fibroadenosis (Mansel 1982) and other benign diseases of the breast, and menorrhagia (Chimbira 1980). Danol can suppress the hormonal fluctuations of the menstrual cycle and might, therefore, be expected to be helpful to patients with the premenstrual syndrome (PMS). Indeed, it appears that many gynaecologists use Danol successfully in PMS although its efficacy has not, until now, been put to the test in doubleblind, placebo-controlled trials.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (3)

Cited by (5)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK